Side effect | No polymorphisms (88 of 109) | TPMT polymorphisms (10/109) | ITPA polymorphisms (12 of 109) | ||||
---|---|---|---|---|---|---|---|
*1/*3A | *1/*3C | *3A/*3A | *3B/*3B | WT/94C>A | 94C>A/94C>A | ||
One patient was included in both the TPMT polymorphisms column and in the ITPA polymorphisms column as he was heterozygous for the TPMT*3A polymorphism and heterozygous for the ITPA 94 C>A polymorphism. Side effects categorised as “other” included rash, renal function disorders, vertigo, myalgia, and arthralgia. | |||||||
None | 54 | 5 | 0 | 0 | 0 | 10 | 0 |
Leucocytes <2×109/l | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Leucocytes 2–4×109/l | 9 | 1 | 0 | 0 | 0 | 0 | 0 |
Hepatotoxicity | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
Pancreatitis | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
Gastrointestinal | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
Other | 8 | 0 | 1 | 0 | 0 | 2 | 0 |
Total | 88 | 7 | 1 | 1 | 1 | 12 | 0 |